title: Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, Cisplatin, and mitomycin chemotherapy.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Shamash
authors.forename: Tom
authors.initials: T
authors.lastname: Powles
authors.forename: Peter
authors.initials: P
authors.lastname: Wilson
authors.forename: Wendy
authors.initials: W
authors.lastname: Ansell
authors.forename: Timothy
authors.initials: T
authors.lastname: Oliver
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D016207:Cytokines / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D006801:Humans; D000077146:Irinotecan; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016685:Mitomycin / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D011379:Prognosis
chemical_list: D016207:Cytokines; D016685:Mitomycin; D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin